すくみ足治療の世界市場規模：製品タイプ別、用途別、地域別、範囲および予測

すくみ足治療の市場規模と予測

すくみ足治療市場規模はここ数年で大幅な成長率で急成長しており、市場推計・予測期間（2021年～2028年）には大きく成長すると予測されています。

パーキンソン病有病率の増加がすくみ足治療市場の成長を牽引世界の老年人口の増加がすくみ足治療市場の最大の促進要因すくみ足治療の世界市場レポートは市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界のすくみ足治療市場の定義

すくみ足（FOG）は、パーキンソン病のドパミン抵抗性運動症状の1つとされることが多いです。パーキンソン病は2番目に多い神経変性疾患であり、60歳以上の成人の約1％が罹患しています。85歳以上では、発症率は3％から5％に上昇します。徐脈、安静時振戦、硬直、姿勢反射の欠如が最も一般的な症状です。病気が進行すると、ほとんどのPD患者は姿勢反射を失い、歩行困難やバランス障害を引き起こします。

前かがみの姿勢、すくみ足治療（FOG）、しゃがみ込み、転倒はすべてPDによくみられる歩行障害です。FOGは、原因不明の効果的なステップの開始不能の発症と定義され、特に障害物、出入り口、ストレス、注意散漫に直面したときのステップの開始と旋回時に最も起こります。レボドパ（L-ドパ）またはエンタカポンによる治療は、最近の研究でOff-関連FOGを改善することが示されています。L-ドパはFOGエピソードの持続時間と頻度を減少させることが示されています。オン関連FOGはまれで、診断が難しいです。FOGは他の多くの症状と同様に、最も進行した病期でのみ治療に抵抗性を示します。

現在までのところ、レボドパはパーキンソン病治療のゴールドスタンダードです。レボドパは運動症状をかなり改善します。高用量のレボドパは、プラセボや低用量のレボドパと比較して、FOGの発生を遅らせ、減少させることができます。レボドパはアキネジアとFOGのエピソード数を有意に減少させる。また、レボドパは「オフ」関連のFOGの頻度と持続時間を減少させることができます。脳深部刺激（DBS）はFOGを改善し、FOGでの転倒を減少させることが示されています。

すくみ足治療治療の世界市場概要

パーキンソン病有病率の増加がすくみ足治療市場の成長を促進しています。すくみ足は、パーキンソン症候群やその他のパーキンソン病の一般的な症状です。すくみ足は転倒や転倒による怪我、自立心の喪失につながることが多いため、患者と家族の双方にとって大きな負担となっています。歩行固縮の治療は、発作的で変化しやすい性質、運動（踏み出し機構の障害）と非運動（認知機能低下、不安）の相互作用を含む包括的な病態生理、複数の神経接続障害を含む複雑な（そしておそらく異質な）基本的神経基盤など、さまざまな要因のために困難です。この疾患はパーキンソン病と関連しているため、市場は健全に成長すると予想されます。

世界の老年人口の増加が市場の最大の促進要因です。ある調査によると、毎年約6万人の北米人がパーキンソン病と診断されており、北米市場は大きな可能性を秘めています。さらに、このような疾患は女性よりも男性の方が開発しやすいことが判明しています。高齢者は病気になりやすく、さまざまな慢性疾患や致命的な病気にかかる可能性が高いだけでなく、脊椎や関節の痛みなど、生涯にわたって痛みを引き起こす障害にかかる可能性も高いからです。しかし、すくみ足に関連する薬を服用した後に副作用を発症する患者もいるため、すくみ足治療市場の成長が抑制される可能性があります。

目次

第1章 世界のすくみ足治療市場：イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次インタビュー
• データソース一覧

第4章 世界のすくみ足治療市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 すくみ足治療の世界市場：製品タイプ別

• 概要
• カルビドパ/レボドパ
• 脳深部刺激療法
• ウェアラブルおよび歩行補助装置

第6章 すくみ足治療の世界市場：用途別

• 概要
• 病院
• 診療所
• その他

第7章 すくみ足治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 世界のすくみ足治療市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第9章 企業プロファイル

• Acorda Therapeutics
• Teva Pharmaceuticals
• GYENNO
• MedEXO Robotics
• APDM, INC

第10章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Freezing Of Gait Treatment Market Size And Forecast

Freezing Of Gait Treatment Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. The growing geriatric population worldwide is the biggest driver of the Freezing Of Gait Treatment Market. The Global Freezing Of Gait Treatment Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Freezing Of Gait Treatment Market Definition

Freezing of gait (FOG) is frequently regarded as one of the dopamine-resistant motor symptoms of Parkinsonism. Parkinson's disease is the second most prevalent neurodegenerative disorder, impacting about 1% of adults over 60 years of age. In persons above the age of 85, the incidence rises from 3% to 5%. Bradykinesia, resting tremor, rigidity, and lack of postural reflexes are the most common symptoms. As the disease progresses, most people with PD lose their postural reflexes, leading to walking difficulties and balance problems.

Stooped posture, freezing of gait (FOG) festination, shuffling steps, and falling are all common PD gait disorders. FOG, defined as an onset of inability to start effective steps without a known cause, is most particularly experienced during step initiation and turning, especially facing obstacles, doorways, stress, and distraction. Treatment with levodopa (L-dopa) or entacapone has been shown to improve Off-related FOG in recent studies. L-dopa has been shown to reduce the duration and frequency of FOG episodes. On-related FOGs are uncommon and difficult to diagnose. FOGs, like many other symptoms, are only resistant to treatment at the most advanced stages of the disease.

To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can considerably improve the symptoms of movement. High-dose levodopa can delay and reduce the occurrence of FOG when compared to placebo or low-dose levodopa. Levodopa can significantly decrease the number of episodes of akinesia and FOG. Levodopa can also reduce the frequency and duration of 'off'-related FOG. Deep brain stimulation (DBS) has been shown to improve FOG and reduce falls in FOG.

Global Freezing Of Gait Treatment Market Overview

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. Freezing of gait is a common symptom of Parkinson's syndrome and several other forms of parkinsonism. Freezing is a major burden for both patients and families since it often leads to falls, injuries from falls, and a loss of independence. Treatment of gait freezing is difficult due to a variety of factors, including its paroxysmal and changeable nature; comprehensive pathophysiology encompassing an interplay among motor (disturbed stepping mechanisms) and non-motor (cognitive decline, anxiety); and a complex (and likely heterogeneous) fundamental neural substrate, which includes multiple failing neural connections. As the disease is correlated with Parkinson's disease, the market is expected to grow healthy.

The growing geriatric population worldwide is the biggest driver of the market. According to a study, around 60,000 Americans are diagnosed with Parkinson's disease every year, therefore the market in North America has a lot of potential. Furthermore, it has been discovered that men are more vulnerable to developing such diseases than women. The rise in the geriatric population is also benefitting the Freezing Of Gait Treatment Market, since older people are more likely to become ill and suffer a variety of chronic or fatal diseases, as well as disorders that cause them pain throughout their life, such as spinal or joint pain. However, some patients develop side effects after taking medications related to the freezing of gait which might restrain the Freezing Of Gait Treatment Market growth.

Global Freezing Of Gait Treatment Market: Segmentation Analysis

The Global Freezing Of Gait Treatment Market is segmented on the basis of Product Type, Application, And Geography.

Freezing Of Gait Treatment Market, By Product Type

• Carbidopa/Levodopa
• Deep Brain Stimulation
• Wearable and Walking Aid Devices

Based on Product Type, The market is segmented into Carbidopa/Levodopa, Deep Brain Stimulation, and Wearable and Walking Aid Devices. Carbidopa/Levodopa segment is expected to grow at a significant rate during forecasted years. To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can significantly decrease the number of episodes of akinesia and FOG.

Freezing Of Gait Treatment Market, By Application

• Hospitals
• Clinics
• Others

Based on Application, The market is segmented into Hospitals, Clinics, and Others. The Hospitals segment is expected to grow at a significant rate during the forecasted years. This is owing to, symptomatic and neuroprotective therapies being preferred in Hospitals, according to FDA and other research studies.

Freezing Of Gait Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Freezing Of Gait Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Owing to the increased frequency of Parkinson's disease in North America especially the United States generated the highest revenue share in the Freezing Of Gait Treatment Market. Rising awareness of new medications and therapies, FDA approvals for new drugs, and an expansion in PD care services, as well as an improved reimbursement structure, will fuel demand in the near future.

Key Players

• The "Global Freezing Of Gait Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM, INC.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In November 2020: MedEXO Robotics is a Hong Kong-based robotics technology company that recently launched the ExoBeam walking device to help people with Parkinson's disease and other movement disorders. For continuous monitoring, the ExoBeam system consists of a small laser projector that can be attached to the wearer's pants, belt, or cane.
• In January 2018: GYENNO, a Chinese firm that develops technologies to help people with Parkinson's disease and other movement disorders, was showing off its Gait Aid Equipment package at the recent CES 2018 conference in Las Vegas.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL FREEZING OF GAIT TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL FREEZING OF GAIT TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Carbidopa/Levodopa
• 5.3 Deep Brain Stimulation
• 5.4 Wearable and Walking Aid Devices

6 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Others

7 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL FREEZING OF GAIT TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Acorda Therapeutics
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Teva Pharmaceuticals
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 GYENNO
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 MedEXO Robotics
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 APDM, INC
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research